Introduction

Earlier this year, former Little Mix star Jesy Nelson shared devastating news: her twins had been diagnosed with spinal muscular atrophy (SMA). SMA is a rare genetic condition characterized by progressive muscle weakness, affecting one’s ability to move, swallow, and even breathe. In its most severe form, babies often don’t survive past early childhood without intensive support.

For Nelson, the hardest part wasn’t just the diagnosis. It was the what if. What if she had known earlier?

In the UK, a program led by Genomics England is trying to change stories like this. The Generation Study Programme aims to sequence the genomes of 100,000 newborns and screen for hundreds of rare but serious genetic conditions, including SMA. Many countries already screen newborns for SMA through standard heel-prick blood tests. But the advantage of whole-genome sequencing is that it can simultaneously flag hundreds of other rare but treatable conditions that current newborn panels miss entirely.

This raises the question: Could she have improved her children’s quality of life, if she had opted for this programme?

SMA

SMA is strongly linked to changes in a single gene, which makes it exactly the kind of condition genome sequencing is designed to catch early. Zolgensma, a gene therapy approved for SMA, works best when administered within the first weeks of life, ideally before symptoms even appear. In infants treated that early, the therapy can support normal motor development and prevent the severe neurological damage that, without early intervention, becomes irreversible.

If the technology exists, and the stakes are this high, the obvious question is:

Why don’t all countries screen newborns this way?

Ethical Concerns

There are several ethical concerns with regards to genome sequencing. One involves the emerging autonomy of the child as a baby cannot consent to having their genetic blueprint recorded. Another is data privacy: who owns that data? Who gets to use it? And what happens if it falls into the wrong hands?

Genomic data doesn’t just identify you but it identifies your entire biological family, even relatives who never consented to anything. Cases like the bankruptcy of 23andMe have only fueled anxiety about what happens to sensitive data over time. There’s also the risk of genetic discrimination by employers or insurers if this information is ever misused.

My Take

Every day, millions of people click “Accept All Cookies” without a second thought. We trade away our data, our habits, preferences, even our location for convenience. We accept our personal data being misused and recorded constantly.

So why does it feel different when the data in question could save a life?

Genomic data is actually better protected legally than the data you give away for free every day. Laws like GINA in the United States and Bill S-201 in Canada explicitly prohibit genetic discrimination by employers and insurers, which are protections that don’t exist for your browsing history or location data. We’re more protected genomically than digitally, and yet we consent to one effortlessly and hesitate at the other.

For diseases like SMA, early diagnosis is essential, as timing can mean the difference between a normal childhood and a lifetime of struggle. The possibility of catching a life-altering rare disease in its earliest stages and potentially saving your child’s life outweighs the risk of privacy concerns.

Would you enroll your future child in a newborn genome sequencing program?

From Pop Stardom to Genomics: Why Jesy Nelson's Story Raises a Bigger Question

Introduction

SMA

Ethical Concerns

My Take

References